China sets ambitious goals for global biopharma expansion in new five-year plan

China’s central government issued its latest five-year plan for the biotech and pharmaceutical sectors on Friday, according to Endpoints News, formalizing goals for the country’s expansion as a global biopharma competitor. The plan follows a period in which Beijing has increasingly signaled intent to compete directly with established Western drugmakers on innovation and market share rather than functioning primarily as a manufacturing base for generics and active pharmaceutical ingredients.

Endpoints News reports that the document sets targets across the industry, part of a broader pattern of state planning cycles that shape investment, regulatory priorities, and research funding across Chinese sectors. The five-year plan format has historically been used by Beijing to direct capital and policy attention toward strategic industries, and its application to biopharma follows several years in which Chinese biotech firms have grown more active in licensing deals, clinical trials, and drug approvals both domestically and abroad.

The report notes that observers who once questioned whether China could become a serious global force in biopharma innovation are seeing that doubt diminish. The five-year plan itself, as described in the report, lays out ambitions for the industry’s international standing over the coming period.

Further specifics of the plan’s targets, timelines, and implementation mechanisms were not detailed in the available material.